Electronic Aci	knowledgement Receipt			
EFS ID:	4875523			
Application Number:	10585892			
International Application Number:				
Confirmation Number:	7625			
Title of Invention:	Use of Quaternary Pyridinium Salts as Vasoprotective Agents			
First Named Inventor/Applicant Name:	Jerzy Gebicki			
Customer Number:	23973			
Filer:	Michele A. Cimbala			
Filer Authorized By:				
Attorney Docket Number:	200045-0003-00-US			
Receipt Date:	27-FEB-2009			
Filing Date:	11-JUL-2006			
Time Stamp:	15:50:24			
Application Type:	U.S. National Stage under 35 USC 371			
Payment information:				

## Submitted with Payment

Information:

File Listin	g:	,			
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	27820010001_SKGFcoverletter. pdf	51069	no	1
			b0449d458513380f5561449c74f8ef30d2d0 9ada		
Warnings:					

no

2 Response to Election / Restriction Filed	27820010001_2ndRRQ_Reply.	48590	no	2	
2	nesponse to Election, nestriction riled	pdf	1350cf96s987e1e639s1c539224565493e6 67a14	110	-
Warnings:	-				
Information	:				
3	Information Disclosure Statement Letter	27820010001_ThirdSupplment al_IDS.pdf		no	2
			e33a13b7e312630d9c5a51c3bce116ca479 as282		
Warnings:					
Information	:				
	Information Disclosure Statement (IDS)	27820010001_PTOSB08A_IDSf	41036	no	1
7	Filed (SB/08)	orm.pdf	b4cd350c7d8a64606x0e2bdd8791e7012d0 8209f		<u> </u>
Warnings:					
Information	:				
This is not an l	JSPTO supplied IDS fillable form				
			175634		
5		27820010001_ThirdPAM.pdf	173034	yes	8
5		27820010001_ThirdPAM.pdf	7209d4acc98fa73dabb159941c10167b1b6	yes	8
5	Multip	27820010001_ThirdPAM.pdf art Description/PDF files in	720934acc98fa73dabb159941c10167b1b6 189a6	yes	8
5	Multip Document Des	art Description/PDF files in	720934acc98fa73dabb159941c10167b1b6 189a6		8 nd
5		art Description/PDF files in . scription	7209344acc98fa73dabb159941c10167b1bf 109a6 zip description	E	
5	Document Des	art Description/PDF files in . scription	720794scc08fa73dabb159941c10167b1bf 17936 zip description Start	E	nd
5	Document Des Preliminary Ame	art Description/PDF files in . scription	22004scc@fiziklade\S904cfel0fizi	E	nd
5 Warnings:	Document Des Preliminary Ame	art Description/PDF files in . scription	27094uccella Madado (1994 to 1984 to 1	E	<b>nd</b> 1
Ĭ	Preliminary Ame Claims Applicant Arguments/Remarks	art Description/PDF files in . scription	27094uccella Madado (1994 to 1984 to 1	E	<b>nd</b> 1

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

## New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-[d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

## National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

## New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810). A Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.